

# Oncology: backing the fight against cancer

Learn about the Tema Oncology ETF, which seeks to provide long-term growth by investing in oncology companies that we have identified as leading the revolution in biology.

**Capital at risk**



## Cancer is the second deadliest killer but could be on the brink of a revolution

**1 in 2  
people**

will be  
diagnosed with  
cancer in their  
lifetime



**\$25  
Trillion**


Estimated global cost  
of cancer from  
2020-2050

**A revolution in biology is driving  
significant advances in diagnosing and  
treating cancer**



# Cancer incidence is primarily driven by an aging global population


70% of diagnoses are made past 60 years old



The population of individuals >60 years old is forecast by the UN to 2.5x **by 2050 to 2.5 billion people**

Source: National Cancer Institute, 1975–2020 data as of June 2023. Both sexes and all ages included. There is no guarantee the Adviser's investment strategy will be successful. UN (2017). World Population Prospects: the 2017 Revision.


# Oncology spending is forecasted to nearly double by 2027



Source: IQVIA Oncology Link, April 2023. Forecasts are inherently limited and should not be relied upon when making investment decisions. There is no guarantee projected growth will occur. In addition, there is no guarantee it will translate to positive fund performance.

# There is a sustained boom in new drug approvals

>100% increase in approved drugs from 2010 to 2021 and Oncology is leading the way




FDA new drug approvals by therapeutic area in 2021

Source: Nature analysis of FDA data, CEDRA a department of FDA. Past performance does not guarantee future results.




# Examples of oncology innovation

## Cell Therapy: harnessing patients’ immune cells to fight cancer




## Early cancer detection saves lives

### Late diagnosis: High mortality rate



### Early diagnosis: Low mortality rate



71% of cancer-related deaths are from cancers with no recommended screening

Liquid biopsies: detecting multiple cancers earlier than before

**healthnews**

Home → Health conditions → Cancer

**Innovations in Cancer Diagnostics: Liquid Biopsies**

Published on March 20, 2023 ·


Miglė Janeliūnienė, PhD  
Author

Source: Adapted from Illumina. SEER program (www.seer.cancer.gov) Stats database: Incidence – SEERS 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50–79 diagnosed 2006–2015. “Early / Localized” includes invasive localized tumors that have not spread beyond organ of origin, “Late / Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.




The investment opportunity has greatly expanded over the past decade due to a significant rise in the number of newly listed oncology companies

Oncology listed universe by IPO year



Source: Bloomberg, Tema proprietary oncology universe. Past performance does not guarantee future results. IPO: Initial public offering.


Why now?  
Worst biotech downcycle in decades,  
nearly 25% of small biotech trade below  
net cash value



Source: Bloomberg. S&P Biotechnology Select Industry Index used for 2008, 2015, 2021 cycles. Cycles start dates are defined by index price peaks for each year. Nasdaq Biotech Index used for 2001 cycle. Past performance is not indicative of future results. The referenced index is shown for informational purposes only and is not meant to represent the Fund. You cannot invest directly in an index. The measures are representative of the indexes underlying holdings and are not indicative of future performance.


Big Pharma has \$838 Bn of dry powder,  
enough to buy 74% of the entire the S&P Biotechnology Select Index

Recent oncology deals have been done  
at high acquisition premiums




Bloomberg, Evaluate Pharma Aug 2022. "Dry powder" defined as total Cash and Cash Equivalents on the top 20 large cap pharma company balance sheets as of 31/12/2022 plus total Free Cash Flow generation over the next three years as forecast by consensus on Bloomberg. The referenced index is shown for informational purposes only and is not meant to represent the Fund. S&P Select Industry Indices are designed to measure the performance of narrow GICS sub-industries. The Index comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry. You cannot invest directly in an index. For a full list of fund holdings [click here](#).

# Tema CANC ETF portfolio: balanced across key oncology areas and company profiles



- Antibodies / Antibody-Drug Conjugates
- Cell Therapy & Gene Editing
- Diagnostics
- Immuno-oncology
- Protein Degradation
- Radiation & Interventional Oncology
- RNA
- Services
- Targeted Therapies
- Tools



- Growth
- Established
- Emerging Biopharma

Source: Tema CANC ETF Portfolio as of 07/31/2023, subject to change. Tema classification based on main business and company drivers. Risk profile is subjective categorization by Tema. Established refers to maturing growth businesses with a long-term history of profitable operations. Growth businesses refer to recently commercialized companies or companies in early stages of rapid growth from a material product cycle, with not yet at scale profit margins. Emerging Biopharma refer to pre-revenue companies. For a full list of fund holdings [click here](#).



Click here to download  
CANC's Investor Deck

[Download Deck](#)

# Back the fight against cancer

## Tema Oncology ETF (CANC)


The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in oncology companies we have identified as leading the fight against cancer.

### Five reasons to consider CANC ETF



#### Impact

Investors can provide capital to companies pioneering cures and early detection of cancer




#### Innovation

The life sciences industry is still in the early stages of a revolution in oncology innovation - from CAR-T cell therapies to bi-specific antibodies - powered by biological insights and growing capabilities




#### Research expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations



#### Uncorrelated

Performance of many biotechnology companies relies on clinical success which is an uncorrelated source of return




#### Growth

Oncology is an increasingly prioritized therapeutic class with treatment spend expected to grow substantially, driven by an aging population; this secular growth trend also tends to be insulated from economic cycles


### CANC portfolio breakdown

Country weighting



- Japan
- United States
- Britain
- Switzerland
- Netherlands
- Denmark
- Germany
- Canada

Market cap bands (\$ Bn)



- 0-1
- 1-2
- 2-5
- 5-10
- 10-50
- >50

Information and data as of 09/30/2023 and subject to change. Figures may not add up to 100% due to rounding.


Click here to learn more  
about CANC's portfolio

[About CANC](#)



Join our newsletter and receive more insightful multimedia content

[Subscribe](#)



## Risk Information

**Before investing carefully consider the Fund's investment objective, risks, charges, and expenses contained in the prospectus available at [www.temaetfs.com](http://www.temaetfs.com). Read carefully before investing.**

Investing involves risk including possible loss of principal. There is no guarantee the adviser's investment strategy will be successful.

**Industry Concentration Risk:** Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

**Biotechnology Industry Risk.** The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

**Oncology Companies Risk.** Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.

Investing in Foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Tema Global Limited serves as the investment adviser to Tema Oncology ETF (the "Fund"), and NEOS Investments, LLC serves as a sub adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA's BrokerCheck.

**For inquiries:** [info@temaetfs.com](mailto:info@temaetfs.com)

